Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

I don't care if we accept workable clinical trials from Germany, if it works in MS lets test it in stroke survivors and get this done. Then we can get our states to allow medical marijuana. One step at a time but only if we as survivors demand it. Ask your doctor to sponsor such research and legislation. If I didn't have to fight spasticity all the time, recovering movement would be a breeze, contrary to Dr. William Landaus' opinion and research articles.

http://tan.sagepub.com/content/5/5/255.abstract?etoc=

Abstract

A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.